Cibc World Markets Corp Purchases New Shares in Savara Inc (NASDAQ:SVRA)

Cibc World Markets Corp bought a new position in shares of Savara Inc (NASDAQ:SVRA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,798 shares of the company’s stock, valued at approximately $33,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. increased its position in Savara by 21.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 837,467 shares of the company’s stock valued at $2,571,000 after acquiring an additional 146,858 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Savara during the fourth quarter valued at approximately $798,000. Charles Schwab Investment Management Inc. boosted its position in Savara by 5.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 963,821 shares of the company’s stock valued at $2,959,000 after buying an additional 52,204 shares during the last quarter. Bank of New York Mellon Corp increased its position in Savara by 7.6% in the fourth quarter. Bank of New York Mellon Corp now owns 253,630 shares of the company’s stock worth $779,000 after purchasing an additional 17,870 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Savara by 6.8% during the 4th quarter. Rhumbline Advisers now owns 141,425 shares of the company’s stock worth $434,000 after buying an additional 9,041 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Trading Up 4.7 %

Shares of NASDAQ SVRA opened at $2.91 on Friday. The stock has a market cap of $499.41 million, a P/E ratio of -6.77 and a beta of 0.60. Savara Inc has a 52-week low of $2.26 and a 52-week high of $5.34. The firm has a 50 day moving average price of $2.72 and a two-hundred day moving average price of $3.26. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The business had revenue of $0.27 million during the quarter. As a group, equities analysts forecast that Savara Inc will post -0.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on SVRA shares. Wells Fargo & Company assumed coverage on Savara in a research note on Friday, December 20th. They issued an “overweight” rating and a $8.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Savara in a report on Friday. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Savara currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.